SCHEMBL1737759

SCHEMBL1737759

COc1ccc(Cn2c(C)c(C)c3cc(Cl)nc(N4CCc5ccccc5C4)c32)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
KDM4E B2RXH2 3/20 0.41
MAPK1 P28482 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ALDH1A1 P00352 6/20 0.41
POLB P06746 1/20 0.41
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TNF P01375 1/20 0.38
NOD2 Q9HC29 1/20 0.38
NOD1 Q9Y239 1/20 0.38
TSHR P16473 2/20 0.38
PRMT5 O14744 3/20 0.38
WDR77 Q9BQA1 3/20 0.38
GAA P10253 1/20 0.38
ALOX15 P16050 1/20 0.38
MEN1 O00255 1/20 0.37
TP53 P04637 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1736732 0.92 SIGMAR1 (0.40) MAPTKDM4EMAPK1NPSR1ALDH1A1
SCHEMBL1737100 0.91 GRIN2D (0.41) MAPTKDM4EMAPK1NPSR1ALDH1A1
SCHEMBL1736856 0.91 ALDH1A1 (0.40) MAPTKDM4EMAPK1NPSR1ALDH1A1
SCHEMBL1736680 0.90 ALDH1A1 (0.42) MAPTKDM4EMAPK1NPSR1ALDH1A1
SCHEMBL1737032 0.90 ALDH1A1 (0.39) MAPTKDM4EMAPK1NPSR1ALDH1A1
SCHEMBL1736907 0.89 HSD17B10 (0.42) MAPTKDM4EMAPK1NPSR1ALDH1A1
SCHEMBL1737013 0.88 ALDH1A1 (0.43) MAPTKDM4EMAPK1NPSR1ALDH1A1
SCHEMBL1736902 0.87 ALDH1A1 (0.38) MAPTKDM4EMAPK1NPSR1ALDH1A1
SCHEMBL1735943 0.86 PRMT5 (0.41) MAPTKDM4EMAPK1NPSR1ALDH1A1
SCHEMBL1740044 0.85 MAPT (0.42) MAPTKDM4EMAPK1NPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1784404-B1 PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORP (KR) 2011-11-16 EP claimed
US-20110263306-A1 COMPUTER SYSTEM AND PROGRAM NAMCO BANDAI GAMES INC. (JP) 2011-10-27 US claimed
US-7662832-B2 Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof YUHAN CORPORATION (KR) 2010-02-16 US claimed
US-20070219230-A1 PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2007-09-20 US claimed
US-8188114-B2 Pyrrolo[2,3-C]pyridine derivatives and processes for the preparation thereof YUHAN CORPORATION (KR) 2012-05-29 US disclosed
US-20100069430-A1 PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2010-03-18 US disclosed
US-7662832-B2 Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof YUHAN CORPORATION (KR) 2010-02-16 US disclosed
US-20070219230-A1 PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069430-A1 PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF PGA5, ATP6AP1, ATP6V1H MAPT 3920/4885KDM4E 1107/4885MAPK1 1781/4885
US-20070219230-A1 PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF PGA5, ATP6AP1, ATP6V1H MAPT 3920/4885KDM4E 1107/4885MAPK1 1781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.